HEADER TRANSFERASE/TRANSFERASE INHIBITOR 25-JAN-15 4XUF TITLE CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR TITLE 2 QUIZARTINIB (AC220) COMPND MOL_ID: 1; COMPND 2 MOLECULE: RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 600-710, 762-947; COMPND 5 SYNONYM: FL CYTOKINE RECEPTOR,FETAL LIVER KINASE-2,FLK-2,FMS-LIKE COMPND 6 TYROSINE KINASE 3,FLT-3,STEM CELL TYROSINE KINASE 1,STK-1; COMPND 7 EC: 2.7.10.1; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: FLT3, CD135, FLK2, STK1; SOURCE 6 EXPRESSION_SYSTEM: UNIDENTIFIED BACULOVIRUS; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 10469 KEYWDS FLT3, RECEPTOR TYROSINE KINASE, AC220, QUIZARTINIB, TRANSFERASE- KEYWDS 2 TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.A.ZORN,Q.WANG,E.FUJIMURA,T.BARROS,J.KURIYAN REVDAT 6 27-SEP-23 4XUF 1 HETSYN REVDAT 5 20-NOV-19 4XUF 1 REMARK REVDAT 4 06-SEP-17 4XUF 1 REMARK REVDAT 3 26-AUG-15 4XUF 1 REMARK REVDAT 2 29-APR-15 4XUF 1 JRNL REVDAT 1 15-APR-15 4XUF 0 JRNL AUTH J.A.ZORN,Q.WANG,E.FUJIMURA,T.BARROS,J.KURIYAN JRNL TITL CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE JRNL TITL 2 INHIBITOR QUIZARTINIB (AC220). JRNL REF PLOS ONE V. 10 21177 2015 JRNL REFN ESSN 1932-6203 JRNL PMID 25837374 JRNL DOI 10.1371/JOURNAL.PONE.0121177 REMARK 2 REMARK 2 RESOLUTION. 3.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: DEV_1839) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 46.46 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.330 REMARK 3 COMPLETENESS FOR RANGE (%) : 91.7 REMARK 3 NUMBER OF REFLECTIONS : 9310 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.299 REMARK 3 R VALUE (WORKING SET) : 0.297 REMARK 3 FREE R VALUE : 0.320 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.010 REMARK 3 FREE R VALUE TEST SET COUNT : 932 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 46.4602 - 6.0659 0.99 1387 153 0.2469 0.2698 REMARK 3 2 6.0659 - 4.8163 1.00 1305 146 0.3006 0.2625 REMARK 3 3 4.8163 - 4.2080 0.96 1256 140 0.2879 0.3139 REMARK 3 4 4.2080 - 3.8234 0.95 1223 135 0.3030 0.3485 REMARK 3 5 3.8234 - 3.5495 0.94 1225 135 0.3429 0.4046 REMARK 3 6 3.5495 - 3.3403 0.90 1137 128 0.3642 0.4014 REMARK 3 7 3.3403 - 3.2000 0.66 845 95 0.3674 0.3884 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.530 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 38.520 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 75.04 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 68.15 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.004 4524 REMARK 3 ANGLE : 0.874 6114 REMARK 3 CHIRALITY : 0.041 650 REMARK 3 PLANARITY : 0.004 761 REMARK 3 DIHEDRAL : 13.841 1668 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : 1 REMARK 3 NCS GROUP : 1 REMARK 3 NCS OPERATOR : 1 REMARK 3 REFERENCE SELECTION: CHAIN A REMARK 3 SELECTION : CHAIN B REMARK 3 ATOM PAIRS NUMBER : 2286 REMARK 3 RMSD : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4XUF COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-MAR-15. REMARK 100 THE DEPOSITION ID IS D_1000206288. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-SEP-14 REMARK 200 TEMPERATURE (KELVIN) : 80 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 8.2.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315R REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 9403 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.200 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.3 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.20900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 5.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.31 REMARK 200 COMPLETENESS FOR SHELL (%) : 77.1 REMARK 200 DATA REDUNDANCY IN SHELL : 2.90 REMARK 200 R MERGE FOR SHELL (I) : 0.59700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHENIX REMARK 200 STARTING MODEL: PDB ENTRY 1RJB REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.96 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.08 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1 M TRIS-HCL, PH 7.5, 32% PEG 3350, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 24.36300 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 76.98400 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 37.74600 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 76.98400 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 24.36300 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 37.74600 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LYS A 649 REMARK 465 ALA A 650 REMARK 465 ASP A 651 REMARK 465 GLU A 708 REMARK 465 LYS A 709 REMARK 465 PHE A 710 REMARK 465 SER A 762 REMARK 465 GLU A 763 REMARK 465 ASP A 764 REMARK 465 GLU A 765 REMARK 465 ILE A 766 REMARK 465 GLU A 767 REMARK 465 TYR A 768 REMARK 465 GLU A 769 REMARK 465 ASN A 770 REMARK 465 GLN A 771 REMARK 465 LYS A 772 REMARK 465 ARG A 773 REMARK 465 LEU A 774 REMARK 465 GLU A 775 REMARK 465 GLU A 776 REMARK 465 GLU A 777 REMARK 465 GLU A 778 REMARK 465 ASP A 779 REMARK 465 LEU A 780 REMARK 465 ASN A 781 REMARK 465 VAL A 782 REMARK 465 GLU B 708 REMARK 465 LYS B 709 REMARK 465 PHE B 710 REMARK 465 SER B 762 REMARK 465 GLU B 763 REMARK 465 ASP B 764 REMARK 465 GLU B 765 REMARK 465 ILE B 766 REMARK 465 GLU B 767 REMARK 465 TYR B 768 REMARK 465 GLU B 769 REMARK 465 ASN B 770 REMARK 465 GLN B 771 REMARK 465 LYS B 772 REMARK 465 ARG B 773 REMARK 465 LEU B 774 REMARK 465 GLU B 775 REMARK 465 GLU B 776 REMARK 465 GLU B 777 REMARK 465 GLU B 778 REMARK 465 ASP B 779 REMARK 465 LEU B 780 REMARK 465 LEU B 947 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O PHE A 942 OE1 GLN A 946 1.74 REMARK 500 NH1 ARG A 845 O LEU A 860 1.97 REMARK 500 NH1 ARG A 707 O LEU A 884 1.98 REMARK 500 OG1 THR A 635 O HOH A 1101 2.13 REMARK 500 O CYS A 695 C44 P30 A 1001 2.13 REMARK 500 OE2 GLU A 661 N1 P30 A 1001 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 ND2 ASN B 609 C41 P30 B 1001 4454 1.75 REMARK 500 ND2 ASN B 609 C44 P30 B 1001 4454 1.85 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 601 -60.31 -99.65 REMARK 500 THR A 820 -165.06 -111.90 REMARK 500 LEU A 832 -3.36 71.69 REMARK 500 LEU B 601 -61.67 -99.12 REMARK 500 LEU B 783 117.43 -160.91 REMARK 500 THR B 820 -167.77 -113.96 REMARK 500 LYS B 823 13.39 58.11 REMARK 500 ARG B 845 -69.35 -129.07 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue P30 A 1001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue P30 B 1001 DBREF 4XUF A 600 710 UNP P36888 FLT3_HUMAN 600 710 DBREF 4XUF A 762 947 UNP P36888 FLT3_HUMAN 762 947 DBREF 4XUF B 600 710 UNP P36888 FLT3_HUMAN 600 710 DBREF 4XUF B 762 947 UNP P36888 FLT3_HUMAN 762 947 SEQRES 1 A 297 ASP LEU LYS TRP GLU PHE PRO ARG GLU ASN LEU GLU PHE SEQRES 2 A 297 GLY LYS VAL LEU GLY SER GLY ALA PHE GLY LYS VAL MET SEQRES 3 A 297 ASN ALA THR ALA TYR GLY ILE SER LYS THR GLY VAL SER SEQRES 4 A 297 ILE GLN VAL ALA VAL LYS MET LEU LYS GLU LYS ALA ASP SEQRES 5 A 297 SER SER GLU ARG GLU ALA LEU MET SER GLU LEU LYS MET SEQRES 6 A 297 MET THR GLN LEU GLY SER HIS GLU ASN ILE VAL ASN LEU SEQRES 7 A 297 LEU GLY ALA CYS THR LEU SER GLY PRO ILE TYR LEU ILE SEQRES 8 A 297 PHE GLU TYR CYS CYS TYR GLY ASP LEU LEU ASN TYR LEU SEQRES 9 A 297 ARG SER LYS ARG GLU LYS PHE SER GLU ASP GLU ILE GLU SEQRES 10 A 297 TYR GLU ASN GLN LYS ARG LEU GLU GLU GLU GLU ASP LEU SEQRES 11 A 297 ASN VAL LEU THR PHE GLU ASP LEU LEU CYS PHE ALA TYR SEQRES 12 A 297 GLN VAL ALA LYS GLY MET GLU PHE LEU GLU PHE LYS SER SEQRES 13 A 297 CYS VAL HIS ARG ASP LEU ALA ALA ARG ASN VAL LEU VAL SEQRES 14 A 297 THR HIS GLY LYS VAL VAL LYS ILE CYS ASP PHE GLY LEU SEQRES 15 A 297 ALA ARG ASP ILE MET SER ASP SER ASN TYR VAL VAL ARG SEQRES 16 A 297 GLY ASN ALA ARG LEU PRO VAL LYS TRP MET ALA PRO GLU SEQRES 17 A 297 SER LEU PHE GLU GLY ILE TYR THR ILE LYS SER ASP VAL SEQRES 18 A 297 TRP SER TYR GLY ILE LEU LEU TRP GLU ILE PHE SER LEU SEQRES 19 A 297 GLY VAL ASN PRO TYR PRO GLY ILE PRO VAL ASP ALA ASN SEQRES 20 A 297 PHE TYR LYS LEU ILE GLN ASN GLY PHE LYS MET ASP GLN SEQRES 21 A 297 PRO PHE TYR ALA THR GLU GLU ILE TYR ILE ILE MET GLN SEQRES 22 A 297 SER CYS TRP ALA PHE ASP SER ARG LYS ARG PRO SER PHE SEQRES 23 A 297 PRO ASN LEU THR SER PHE LEU GLY CYS GLN LEU SEQRES 1 B 297 ASP LEU LYS TRP GLU PHE PRO ARG GLU ASN LEU GLU PHE SEQRES 2 B 297 GLY LYS VAL LEU GLY SER GLY ALA PHE GLY LYS VAL MET SEQRES 3 B 297 ASN ALA THR ALA TYR GLY ILE SER LYS THR GLY VAL SER SEQRES 4 B 297 ILE GLN VAL ALA VAL LYS MET LEU LYS GLU LYS ALA ASP SEQRES 5 B 297 SER SER GLU ARG GLU ALA LEU MET SER GLU LEU LYS MET SEQRES 6 B 297 MET THR GLN LEU GLY SER HIS GLU ASN ILE VAL ASN LEU SEQRES 7 B 297 LEU GLY ALA CYS THR LEU SER GLY PRO ILE TYR LEU ILE SEQRES 8 B 297 PHE GLU TYR CYS CYS TYR GLY ASP LEU LEU ASN TYR LEU SEQRES 9 B 297 ARG SER LYS ARG GLU LYS PHE SER GLU ASP GLU ILE GLU SEQRES 10 B 297 TYR GLU ASN GLN LYS ARG LEU GLU GLU GLU GLU ASP LEU SEQRES 11 B 297 ASN VAL LEU THR PHE GLU ASP LEU LEU CYS PHE ALA TYR SEQRES 12 B 297 GLN VAL ALA LYS GLY MET GLU PHE LEU GLU PHE LYS SER SEQRES 13 B 297 CYS VAL HIS ARG ASP LEU ALA ALA ARG ASN VAL LEU VAL SEQRES 14 B 297 THR HIS GLY LYS VAL VAL LYS ILE CYS ASP PHE GLY LEU SEQRES 15 B 297 ALA ARG ASP ILE MET SER ASP SER ASN TYR VAL VAL ARG SEQRES 16 B 297 GLY ASN ALA ARG LEU PRO VAL LYS TRP MET ALA PRO GLU SEQRES 17 B 297 SER LEU PHE GLU GLY ILE TYR THR ILE LYS SER ASP VAL SEQRES 18 B 297 TRP SER TYR GLY ILE LEU LEU TRP GLU ILE PHE SER LEU SEQRES 19 B 297 GLY VAL ASN PRO TYR PRO GLY ILE PRO VAL ASP ALA ASN SEQRES 20 B 297 PHE TYR LYS LEU ILE GLN ASN GLY PHE LYS MET ASP GLN SEQRES 21 B 297 PRO PHE TYR ALA THR GLU GLU ILE TYR ILE ILE MET GLN SEQRES 22 B 297 SER CYS TRP ALA PHE ASP SER ARG LYS ARG PRO SER PHE SEQRES 23 B 297 PRO ASN LEU THR SER PHE LEU GLY CYS GLN LEU HET P30 A1001 40 HET P30 B1001 40 HETNAM P30 1-(5-TERT-BUTYL-1,2-OXAZOL-3-YL)-3-(4-{7-[2-(MORPHOLIN- HETNAM 2 P30 4-YL)ETHOXY]IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2- HETNAM 3 P30 YL}PHENYL)UREA HETSYN P30 QUIZARTINIB; PLX3397 FORMUL 3 P30 2(C29 H32 N6 O4 S) FORMUL 5 HOH *2(H2 O) HELIX 1 AA1 PRO A 606 GLU A 608 5 3 HELIX 2 AA2 GLU A 654 GLY A 669 1 16 HELIX 3 AA3 ASP A 698 ARG A 707 1 10 HELIX 4 AA4 THR A 784 LYS A 805 1 22 HELIX 5 AA5 LYS A 853 MET A 855 5 3 HELIX 6 AA6 ALA A 856 GLU A 862 1 7 HELIX 7 AA7 THR A 866 SER A 883 1 18 HELIX 8 AA8 ASP A 895 ASN A 904 1 10 HELIX 9 AA9 THR A 915 TRP A 926 1 12 HELIX 10 AB1 SER A 935 CYS A 945 1 11 HELIX 11 AB2 ASP B 651 GLY B 669 1 19 HELIX 12 AB3 ASP B 698 ARG B 707 1 10 HELIX 13 AB4 THR B 784 LYS B 805 1 22 HELIX 14 AB5 ALA B 813 ARG B 815 5 3 HELIX 15 AB6 PRO B 851 MET B 855 5 5 HELIX 16 AB7 ALA B 856 GLU B 862 1 7 HELIX 17 AB8 THR B 866 SER B 883 1 18 HELIX 18 AB9 ASP B 895 ASN B 904 1 10 HELIX 19 AC1 THR B 915 TRP B 926 1 12 HELIX 20 AC2 SER B 935 GLN B 946 1 12 SHEET 1 AA1 5 LEU A 610 SER A 618 0 SHEET 2 AA1 5 GLY A 622 ALA A 629 -1 O VAL A 624 N LEU A 616 SHEET 3 AA1 5 ILE A 639 LEU A 646 -1 O MET A 645 N LYS A 623 SHEET 4 AA1 5 TYR A 688 GLU A 692 -1 O PHE A 691 N ALA A 642 SHEET 5 AA1 5 LEU A 677 CYS A 681 -1 N CYS A 681 O TYR A 688 SHEET 1 AA2 2 VAL A 817 VAL A 819 0 SHEET 2 AA2 2 VAL A 825 ILE A 827 -1 O LYS A 826 N LEU A 818 SHEET 1 AA3 2 TYR A 842 VAL A 844 0 SHEET 2 AA3 2 ARG A 849 PRO A 851 -1 O LEU A 850 N VAL A 843 SHEET 1 AA4 5 LEU B 610 SER B 618 0 SHEET 2 AA4 5 GLY B 622 TYR B 630 -1 O ASN B 626 N LYS B 614 SHEET 3 AA4 5 SER B 638 LEU B 646 -1 O VAL B 643 N MET B 625 SHEET 4 AA4 5 TYR B 688 GLU B 692 -1 O PHE B 691 N ALA B 642 SHEET 5 AA4 5 LEU B 677 CYS B 681 -1 N CYS B 681 O TYR B 688 SHEET 1 AA5 2 VAL B 817 VAL B 819 0 SHEET 2 AA5 2 VAL B 825 ILE B 827 -1 O LYS B 826 N LEU B 818 SHEET 1 AA6 2 VAL B 843 VAL B 844 0 SHEET 2 AA6 2 ARG B 849 LEU B 850 -1 O LEU B 850 N VAL B 843 SITE 1 AC1 17 LEU A 616 TYR A 630 ALA A 642 GLU A 661 SITE 2 AC1 17 MET A 664 MET A 665 ILE A 674 VAL A 675 SITE 3 AC1 17 CYS A 694 CYS A 695 TYR A 696 GLY A 697 SITE 4 AC1 17 HIS A 809 LEU A 818 ILE A 827 CYS A 828 SITE 5 AC1 17 ASP A 829 SITE 1 AC2 17 ASN B 609 LEU B 616 TYR B 630 ALA B 642 SITE 2 AC2 17 LYS B 644 GLU B 661 MET B 664 MET B 665 SITE 3 AC2 17 ILE B 674 TYR B 693 CYS B 694 CYS B 695 SITE 4 AC2 17 HIS B 809 LEU B 818 CYS B 828 ASP B 829 SITE 5 AC2 17 PHE B 830 CRYST1 48.726 75.492 153.968 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020523 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013246 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006495 0.00000